Market Overview

UPDATE: JMP Securities Reiterates Coverage on ARIAD Pharmaceuticals, Sees Market Share Regain

Related ARIA
GNC, Southern Copper And Others Insiders Have Been Buying
ARIAD Announces Commercial Agreement for Iclusig (Ponatinib) in Israel

In a report published Monday, JMP Securities analyst Michael King reiterated Market Outperform on ARAID Pharmaceuticals, Inc. (NASDAQ: ARIA), with a $10.00 price target.

According to the report, ARIA is gearing up to recapture market share in both the T315I and later-line CML market with a restored, slimmed-down version of its sales force specifically targeting high prescription writers.

“FY14 should continue to be a catalyst-filled year with several data updates planned for ASCO (including GIST data) and EHA, along with the start of the randomized multi-dose study that should commence by 2H14,” the report noted. “Overall, management commentary on several fronts reinforces our positive outlook for 2014.”

ARIA closed Friday at $6.74.

Posted-In: JMP Securities Michael KingAnalyst Color Reiteration Analyst Ratings

 

Related Articles (ARIA)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters